BTIG Research has recently initiated Douglas Elliman Inc (DOUG) stock to Neutral rating, as announced on July 18, 2023, according to Finviz. Analyst ratings are significant because they provide ...
BTIG analyst Marvin Fong raised the firm’s price target on RealReal (REAL) to $5.50 from $4 and keeps a Buy rating on the shares. The firm ...
Fintel reports that on November 19, 2024, BTIG upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from Neutral ...
Jonathan Krinsky, BTIG chief market technician, joins CNBC's Closing Bell to discuss market outlooks.
Energy and Infrastructure Transition Analyst Lewis holds a virtual meeting with management on November 22 hosted by BTIG. Don't Miss out on Research Tools: Discover the latest stocks recommended by ...
CEO of Simulations Plus, Shawn O’Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on ...
NEW YORK--(BUSINESS WIRE)--BTIG announced today that its Digital Health Forum will take place on Monday, November 25, 2024. The event will be hosted by David Larsen, CFA, BTIG Healthcare IT and ...
BTIG Research began coverage on shares of VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a ...
Plug Power (NASDAQ:PLUG) -1.1% in Thursday's trading as BTIG Research downgrades shares to Neutral from Buy, saying the company is "turning the corner but still [has] a lot of work to do." ...
BTIG is “struggling to find any good reason” for why Paysafe (PSFE) is trading down 25% today following its Q3 earnings report. The report was solid with top- and bottom-line beats and a ...
BTIG upgraded Wingstop (NASDAQ:WING) to Buy with a price target of $370 on Thursday, citing opportunities for long-term growth despite recent concerns around the company's fourth-quarter same-store ...
Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...